Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
Sponsor: ModernaTX, Inc.
Summary
The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.
Official title: A Phase 1, Randomized, Open-label Study to Evaluate Safety, Reactogenicity, and Immunogenicity of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, Following Intradermal and Intramuscular Delivery in Healthy Adults 18 to 30 Years of Age
Key Details
Gender
All
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-03-17
Completion Date
2027-05-15
Last Updated
2026-03-24
Healthy Volunteers
Yes
Conditions
Interventions
mRNA-1189
Sterile liquid for injection
Locations (2)
Nucleus Network
Melbourne, Victoria, Australia
Doherty Clinical Trials
Melbourne, Victoria, Australia